Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$9.74 USD
+0.57 (6.22%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $9.42 -0.32 (-3.29%) 5:56 PM ET
1-Strong Buy of 5 1
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.74 USD
+0.57 (6.22%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $9.42 -0.32 (-3.29%) 5:56 PM ET
1-Strong Buy of 5 1
F Value B Growth A Momentum C VGM
Zacks News
Agios' (AGIO) Q3 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo. Stock inches up.
ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y
by Zacks Equity Research
ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.
What's in the Cards for CVS Health (CVS) in Q3 Earnings?
by Zacks Equity Research
CVS Health's (CVS) Q3 earnings might have been affected by issues like lower prescription and soft front store volume due to decline in provider visits.
National Vision (EYE) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
National Vision's (EYE) contact lens revenue growth is expected to have remained impressive in Q3 on lesser impact of store closures.
Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Blueprint Medicines' (BPMC) both bottom and the top line trump estimates in Q3. Ayvakit's sales rise sequentially.
Why Earnings Season Could Be Great for Fulcrum Therapeutics (FULC)
by Zacks Equity Research
Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bionano (BNGO) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Bionano's (BNGO) sales numbers will be in focus when it reports Q2 results later in the week.
5 Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Kinjel Shah
Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.
Fulcrum Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Fulcrum Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Is Fulcrum Therapeutics (FULC) Stock a Solid Choice Right Now?
by Zacks Equity Research
Fulcrum Therapeutics (FULC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Fulcrum Therapeutics, Inc. (FULC) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics, Inc. (FULC).
Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease
by Zacks Equity Research
Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.
Company News For Aug 20, 2019
by Zacks Equity Research
Companies in the news are: EL, PANW, WB and FULC